This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n4http://linked.opendata.cz/resource/domain/vavai/subjekt/
n3http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/
n17http://bibframe.org/vocab/
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064173%3A_____%2F12%3A43901007%21RIV13-MZ0-00064173/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n12http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064173%3A_____%2F12%3A43901007%21RIV13-MZ0-00064173
rdf:type
n3:Vysledek skos:Concept
dcterms:description
The treatment of acute coronary syndromes (ACS) is currently undergoing an interesting evolution due to the introduction of some novel antithrombotic drugs. The available evidence on new oral antiplatelet agents can be summarized as follows: (1) the new drugs (prasugrel and ticagrelor) are faster, more potent, and more predictable than clopidogrel, and thus prasugrel or ticagrelor may replace clopidogrel in most patients with ACS; (2) prasugrel seems to have a more pronounced acute effect, especially in patients with acute ST-elevation myocardial infarction (STEMI), and thus prasugrel may be the preferred drug for STEMI, especially for the acute phase; (3) ticagrelor seems to have better secondary preventive effects in the long term, which may be advantageous for patients with acute non-STEMI; and (4) both new drugs have some contraindications or unpleasant side effects and are both substantially more expensive, which may keep a place in therapy for clopidogrel for selected patients The treatment of acute coronary syndromes (ACS) is currently undergoing an interesting evolution due to the introduction of some novel antithrombotic drugs. The available evidence on new oral antiplatelet agents can be summarized as follows: (1) the new drugs (prasugrel and ticagrelor) are faster, more potent, and more predictable than clopidogrel, and thus prasugrel or ticagrelor may replace clopidogrel in most patients with ACS; (2) prasugrel seems to have a more pronounced acute effect, especially in patients with acute ST-elevation myocardial infarction (STEMI), and thus prasugrel may be the preferred drug for STEMI, especially for the acute phase; (3) ticagrelor seems to have better secondary preventive effects in the long term, which may be advantageous for patients with acute non-STEMI; and (4) both new drugs have some contraindications or unpleasant side effects and are both substantially more expensive, which may keep a place in therapy for clopidogrel for selected patients
dcterms:title
Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents
skos:prefLabel
Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents
skos:notation
RIV/00064173:_____/12:43901007!RIV13-MZ0-00064173
n3:predkladatel
n4:ico%3A00064173
n5:aktivita
n13:N
n5:aktivity
N
n5:cisloPeriodika
1
n5:dodaniDat
n12:2013
n5:domaciTvurceVysledku
n18:2228734
n5:druhVysledku
n14:J
n5:duvernostUdaju
n6:S
n5:entitaPredkladatele
n15:predkladatel
n5:idSjednocenehoVysledku
135338
n5:idVysledku
RIV/00064173:_____/12:43901007
n5:jazykVysledku
n16:eng
n5:klicovaSlova
Ticagrelor; Prasugrel; Oral antiplatelet drugs; Clopidogrel; Acute myocardial infarction; Acute coronary syndrome
n5:klicoveSlovo
n9:Acute%20myocardial%20infarction n9:Clopidogrel n9:Oral%20antiplatelet%20drugs n9:Prasugrel n9:Acute%20coronary%20syndrome n9:Ticagrelor
n5:kodStatuVydavatele
CZ - Česká republika
n5:kontrolniKodProRIV
[1758FC4A7538]
n5:nazevZdroje
Cor et Vasa
n5:obor
n8:FA
n5:pocetDomacichTvurcuVysledku
1
n5:pocetTvurcuVysledku
7
n5:rokUplatneniVysledku
n12:2012
n5:svazekPeriodika
54
n5:tvurceVysledku
Widimský, Petr
s:issn
0010-8650
s:numberOfPages
7
n17:doi
10.1016/j.crvasa.2011.12.004